Silo pharma achieves key milestone with first dosing in ind-enabling glp study for spc-15 as a groundbreaking ptsd treatment

Preclinical data to support advancement toward first-in-human clinical trials sarasota, fl, march 26, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced first dosing in an investigational new drug (ind)-enabling glp (good laboratory practice)-compliant toxicology and toxicokinetics study of its lead asset, spc-15, an intranasal prophylactic treatment for post-traumatic stress disorder (ptsd). “this ind-enabling safety study and our concurrent glp-compliant pharmacokinetic and pharmacodynamic study, if successful, will provide the last preclinical data needed to open an ind for spc-15,” said eric weisblum, ceo of silo.
SILO Ratings Summary
SILO Quant Ranking